Skip to content
10-Q

Quarterly Report

ALDER BIOPHARMACEUTICALS INC

0001564590-19-015330

← back to feed
Filed
May 2, 2019 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2019 · Apr 25, 2019 83.5M sh
Capex Q1 2019 · Mar 31, 2019 $303K
Capex Q1 2019 · Mar 31, 2018 $212K
Operating Cash Flow Q1 2019 · Mar 31, 2019 −$74.58M
Operating Cash Flow Q1 2019 · Mar 31, 2018 −$74.1M
Long Term Debt Q1 2019 · Mar 31, 2019 $185.15M
Cash And Equivalents Q1 2019 · Mar 31, 2019 $126.11M
Cash And Equivalents Q1 2019 · Dec 31, 2018 $87.87M
Stockholders Equity Q1 2019 · Mar 31, 2019 $157.05M
Stockholders Equity Q1 2019 · Dec 31, 2018 $109.98M
Stockholders Equity Q1 2019 · Mar 31, 2018 $302.4M
Stockholders Equity Q1 2019 · Dec 31, 2017 $279.28M
Current Liabilities Q1 2019 · Mar 31, 2019 $60.26M
Current Liabilities Q1 2019 · Dec 31, 2018 $28.24M
Total Liabilities Q1 2019 · Mar 31, 2019 $252.36M
Total Liabilities Q1 2019 · Dec 31, 2018 $212.51M
Current Assets Q1 2019 · Mar 31, 2019 $502.31M
Current Assets Q1 2019 · Dec 31, 2018 $419.81M
Total Assets Q1 2019 · Mar 31, 2019 $513.17M
Total Assets Q1 2019 · Dec 31, 2018 $426.24M
Sga Expense Q1 2019 · Mar 31, 2019 $44.5M
Sga Expense restated Q1 2019 · Mar 31, 2018 $11.55M
Rd Expense Q1 2019 · Mar 31, 2019 $69.59M
Rd Expense Q1 2019 · Mar 31, 2018 $74.05M
Net Income Q1 2019 · Mar 31, 2019 −$117.93M
Net Income Q1 2019 · Mar 31, 2018 −$87.03M
Operating Income Q1 2019 · Mar 31, 2019 −$114.09M
Operating Income restated Q1 2019 · Mar 31, 2018 −$85.6M
Revenue Q1 2019 · Mar 31, 2019 $0
Revenue Q1 2019 · Mar 31, 2018 $0